Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $28.0 million.

  • Ultragenyx Pharmaceutical's Other Operating Expenses rose 33.16% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 34.31%. This contributed to the annual value of $76.7 million for FY2024, which is 69.72% up from last year.
  • Ultragenyx Pharmaceutical's Other Operating Expenses amounted to $28.0 million in Q3 2025, which was up 21.69% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Other Operating Expenses registered a high of $28.7 million during Q1 2025, and its lowest value of $3.1 million during Q2 2021.
  • Its 3-year average for Other Operating Expenses is $18.3 million, with a median of $17.5 million in 2024.
  • Data for Ultragenyx Pharmaceutical's Other Operating Expenses shows a peak YoY increase of 248.10% (in 2021) and a maximum YoY decrease of 35.98% (in 2021) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Operating Expenses (Quarterly) stood at $3.5 million in 2021, then surged by 51.58% to $5.3 million in 2022, then surged by 126.57% to $12.1 million in 2023, then surged by 40.19% to $16.9 million in 2024, then soared by 33.16% to $28.0 million in 2025.
  • Its Other Operating Expenses was $28.0 million in Q3 2025, compared to $23.0 million in Q2 2025 and $28.7 million in Q1 2025.